The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
Researchers from the UK and Belgium identified more than 50 different cell states in the human thymus.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.
The commission plans to bar Bio-Rad from importing certain single-cell products, potentially including the ddSeq Single-Cell Isolator and ddSeq cartridges.
The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH.
10x Genomics sued Harvard University and 1CellBio, a competing single-cell technology firm, in 2018 over licenses for patents granted to both companies.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.
The partners will combine the capabilities of S2's Singulator instrument for solid tissue preparation and Dolomite Bio's Nadia single-cell sample prep platform.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.